Paper36960966
Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.
Ramos-Gonzalez MR and 4 others. Noncoding RNA, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model. Papers, record 36960966. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36960966
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 371665 | Consejo Nacional de Ciencia y Tecnología | PubMed |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24384374 | Liposomal siRNA nanocarriers for cancer therapy. | Adv Drug Deliv Rev | 2014 | https://conductscience.org/library/papers/24384374 | PubMed |
| 2 | 21744502 | Current progress of siRNA/shRNA therapeutics in clinical trials. | Biotechnol J | 2011 | https://conductscience.org/library/papers/21744502 | PubMed |
| 3 | 23237552 | On the origin of cancer metastasis. | Crit Rev Oncog | 2013 | https://conductscience.org/library/papers/23237552 | PubMed |
| 4 | 20220130 | A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20220130 | PubMed |
| 5 | 12654731 | siRNAs: a new wave of RNA-based therapeutics. | J Antimicrob Chemother | 2003 | https://conductscience.org/library/papers/12654731 | PubMed |
| 6 | 22734758 | Monitoring the process of pulmonary melanoma metastasis using large area and label-free nonlinear optical microscopy. | J Biomed Opt | 2012 | https://conductscience.org/library/papers/22734758 | PubMed |
| 7 | 12750711 | An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. | Leukemia | 2003 | https://conductscience.org/library/papers/12750711 | PubMed |
| 8 | 21256590 | Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. | Leuk Res | 2011 | https://conductscience.org/library/papers/21256590 | PubMed |
| 9 | 19461674 | WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. | Cancer Gene Ther | 2009 | https://conductscience.org/library/papers/19461674 | PubMed |
| 10 | 22276610 | High Wilms' tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma. | Histopathology | 2012 | https://conductscience.org/library/papers/22276610 | PubMed |
| 11 | 17912546 | The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. | Pflugers Arch | 2008 | https://conductscience.org/library/papers/17912546 | PubMed |
| 12 | 17109636 | Different isoforms of the Wilms' tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus. | Cell Prolif | 2006 | https://conductscience.org/library/papers/17109636 | PubMed |
| 13 | 29116019 | CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. | J Exp Clin Cancer Res | 2017 | https://conductscience.org/library/papers/29116019 | PubMed |
| 14 | 22903384 | Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. | J Cancer Res Clin Oncol | 2013 | https://conductscience.org/library/papers/22903384 | PubMed |
| 15 | 22933380 | Psycho-educational interventions for melanoma survivors: a systematic review. | Psychooncology | 2013 | https://conductscience.org/library/papers/22933380 | PubMed |
| 16 | 27779659 | microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells. | Mol Med Rep | 2016 | https://conductscience.org/library/papers/27779659 | PubMed |
| 17 | 19392599 | Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. | J Neurosurg | 2010 | https://conductscience.org/library/papers/19392599 | PubMed |
| 18 | 7808002 | The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. | Leukemia | 1994 | https://conductscience.org/library/papers/7808002 | PubMed |
| 19 | 20885852 | WT1 and kidney progenitor cells. | Organogenesis | 2010 | https://conductscience.org/library/papers/20885852 | PubMed |
| 20 | 22887049 | Galangin inhibits tumor growth and metastasis of B16F10 melanoma. | J Cell Biochem | 2013 | https://conductscience.org/library/papers/22887049 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41171469 | WT1 gene: a potential therapeutic target for multiple cancer treatment strategies. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41171469 | PubMed |
| 40724842 | Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40724842 | PubMed |
| 40125426 | A Novel Systemic siDR6 Delivery System Based on DP7-C for the Treatment of Metastatic Lung Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40125426 | PubMed |
| 38106451 | A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/38106451 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAX | 581 | PubTator's text mining | https://conductscience.org/library/genes/581 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| DCTN6 | 10671 | PubTator's text mining | https://conductscience.org/library/genes/10671 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| WT1 | 7490 | PubTator's text mining | https://conductscience.org/library/genes/7490 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36960966
GET https://conductscience.org/api/papers/v1/36960966/references?page=2